Skip to main content

Shigellosis

3
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
2 programs
1
1
Shigella conjugate vaccinesPhase 31 trial
CPPhase 11 trial
Active Trials
NCT01399424Withdrawn0Est. Apr 2012
NCT00368316Completed2,799Est. Feb 2009
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
Tebipenem PivoxilPhase 2
GSK
GSKLONDON, United Kingdom
3 programs
S. sonnei 1790GAHBPHASE_11 trial
S. sonnei 1790GAHBPHASE_11 trial
Tebipenem PivoxilPHASE_21 trial
Active Trials
NCT02017899Completed50Est. Mar 2015
NCT02034500Completed52Est. Apr 2015
NCT05121974Active Not Recruiting132Est. Aug 2026
Labcorp
LabcorpBURLINGTON, NC
1 program
Tebipenem PivoxilPHASE_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Human BioSciencesShigella conjugate vaccines
GSKTebipenem Pivoxil
GSKS. sonnei 1790GAHB
GSKS. sonnei 1790GAHB
Human BioSciencesCP

Clinical Trials (5)

Total enrollment: 3,033 patients across 5 trials

NCT00368316Human BioSciencesShigella conjugate vaccines

Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel

Start: Jan 2003Est. completion: Feb 20092,799 patients
Phase 3Completed
NCT05121974GSKTebipenem Pivoxil

Tebipenem Trial in Children With Shigellosis

Start: Aug 2022Est. completion: Aug 2026132 patients
Phase 2Active Not Recruiting
NCT02034500GSKS. sonnei 1790GAHB

Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults

Start: Mar 2014Est. completion: Apr 201552 patients
Phase 1Completed
NCT02017899GSKS. sonnei 1790GAHB

A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.

Start: Feb 2014Est. completion: Mar 201550 patients
Phase 1Completed
NCT01399424Human BioSciencesCP

Shigella Sonnei OSPC-rDT Conjugate Vaccine

Start: Jul 2011Est. completion: Apr 20120
Phase 1Withdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.